How to Help Your Patients Find Rinvoq XR in Stock: A Provider's Guide

When you prescribe Rinvoq XR (upadacitinib) for a patient, the clinical decision is only the first step. Getting the medication into your patient's hands — quickly and at an affordable cost — is a complex logistical process that often falls on your office staff to manage. This guide gives you a practical playbook to streamline Rinvoq XR access for every patient.

Why Rinvoq XR Access Is Different From Standard Prescriptions

Rinvoq XR is a specialty medication with a wholesale list price of $7,090.41 per month as of January 2026. This classification means:

It cannot be dispensed at standard retail pharmacies in most cases — only specialty pharmacy networks

Prior authorization is required by nearly all insurers

Step therapy (documented TNF inhibitor failure) is required by most plans before coverage

If PA is denied, appeals and peer-to-peer reviews may be necessary

Step 1: Route to the Right Specialty Pharmacy Immediately

The single biggest delay in getting Rinvoq XR to patients is routing the prescription to the wrong place. Always verify which specialty pharmacy is in-network for your patient's insurance before submitting the prescription. The major options include:

Accredo (Express Scripts/Cigna)

CVS Specialty (Aetna)

Optum Rx Specialty (UnitedHealth)

Walgreens Specialty (multiple plans)

AllianceRx Walgreens Prime (preferred for some Blue Cross plans)

Alternatively, use AbbVie's Rinvoq Complete Hub: 1-800-274-6867. Their team will verify the patient's insurance and route to the in-network specialty pharmacy automatically.

Step 2: Build a Complete PA Submission the First Time

Incomplete PA submissions are the primary cause of delays. Include the following in every initial PA request for Rinvoq XR:

Diagnosis with ICD-10 code and disease severity documentation

Prior therapy log: exact drug names, start/stop dates, doses, and reason for discontinuation

Recent labs: CBC with differential, LFTs, lipid panel

TB screening results and treatment status if latent TB identified

Hepatitis B and C serology

Letter of medical necessity if condition is urgent or prior therapy is contraindicated

Step 3: Use Pharmacy Inventory Tools to Find Stock Quickly

Once the PA is approved and the prescription is ready, help your patient find available stock quickly. Medfinder for Providers offers a real-time pharmacy inventory search that shows which pharmacies near your patient have their specific dose of Rinvoq XR in stock. This eliminates the back-and-forth between patient, pharmacy, and your office.

Step 4: Enroll Patients in Savings Programs Before They Leave the Office

Cost is a leading reason patients don't fill specialty prescriptions. Enroll patients in applicable programs at the time of prescribing:

Rinvoq Complete Savings Card — for commercially insured patients. Reduces out-of-pocket to as little as $5/month (up to $14,000/year savings). Available at rinvoq.com or via 1-800-274-6867.

myAbbVieAssist — free medication for up to 12 months for uninsured or underinsured patients. Renewable.

Medicare Extra Help — for low-income Medicare patients, may reduce out-of-pocket cost significantly. Medicare Part D 2026 cap is $2,100/year.

Step 5: Set Up a Refill Monitoring Process

Once a patient is successfully on Rinvoq XR, don't assume the access will remain smooth without intervention. Build these into your workflow:

Calendar PA renewal 60 days before expiration (most authorizations last 6 or 12 months)

Note insurance plan year changes — patients who change insurance in January often need a new PA immediately

Set up auto-refill at the specialty pharmacy so patients don't accidentally run out

Conduct labs required for annual PA renewals in advance — don't wait for the renewal to be triggered

When to Consider Alternative Therapies

If access to Rinvoq XR is delayed more than 2–3 weeks and the patient's disease is active, consider bridge therapy. Oral prednisone for short-term flare control is appropriate for most indications while waiting for PA. If the PA is denied after multiple appeals, a condition-matched alternative may be necessary — such as baricitinib (Olumiant) for RA or dupilumab (Dupixent) for atopic dermatitis.